- Home
- CIGL vs MAIA Comparison
CIGL vs MAIA Comparison
Compare CIGL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- MAIA
- Stock Information
- Founded
- CIGL 1997
- MAIA 2018
- Country
- CIGL Singapore
- MAIA United States
- Employees
- CIGL N/A
- MAIA N/A
- Industry
- CIGL Diversified Commercial Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CIGL Consumer Discretionary
- MAIA Health Care
- Exchange
- CIGL Nasdaq
- MAIA Nasdaq
- Market Cap
- CIGL 52.8M
- MAIA 44.9M
- IPO Year
- CIGL 2025
- MAIA 2022
- Fundamental
- Price
- CIGL $1.80
- MAIA $1.12
- Analyst Decision
- CIGL
- MAIA
- Analyst Count
- CIGL 0
- MAIA 0
- Target Price
- CIGL N/A
- MAIA N/A
- AVG Volume (30 Days)
- CIGL 15.3K
- MAIA 218.7K
- Earning Date
- CIGL 09-29-2025
- MAIA 11-07-2025
- Dividend Yield
- CIGL N/A
- MAIA N/A
- EPS Growth
- CIGL N/A
- MAIA N/A
- EPS
- CIGL N/A
- MAIA N/A
- Revenue
- CIGL $11,072,733.00
- MAIA N/A
- Revenue This Year
- CIGL N/A
- MAIA N/A
- Revenue Next Year
- CIGL N/A
- MAIA N/A
- P/E Ratio
- CIGL N/A
- MAIA N/A
- Revenue Growth
- CIGL 6.32
- MAIA N/A
- 52 Week Low
- CIGL $1.40
- MAIA $0.87
- 52 Week High
- CIGL $31.06
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- MAIA 49.13
- Support Level
- CIGL N/A
- MAIA $0.87
- Resistance Level
- CIGL N/A
- MAIA $1.09
- Average True Range (ATR)
- CIGL 0.00
- MAIA 0.08
- MACD
- CIGL 0.00
- MAIA 0.02
- Stochastic Oscillator
- CIGL 0.00
- MAIA 86.21
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.